Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen ...

Pfizer is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.Shares are down 19% over the past ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. The company said it halted development of danuglipron, an oral ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial. The setback blows a hole in the Big Pharma’s plans to challenge for ...

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

Matthew Herper covers medical innovation — both its promise and its perils. Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron ...

Pfizer shares fell 1.32% after reports U.S. prosecutors are investigating claims from GSK about the timing of Pfizer’s COVID-19 vaccine. Pfizer denies allegations of delaying vaccine results for ...

British drugmaker GSK told Manhattan prosecutors that a former employee told colleagues Pfizer held back positive results until after the 2020 election. But the former employee, who worked at both ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management reaffirmed expectations for 2025 revenue of $61 billion-$64 billion ...